Assay
Financial-condition grades for SEC filers
Company Report · as of Oct 9, 2026
|
| Sarepta Therapeutics, Inc.SRPT · healthcare | |
|---|---|
| Grade |  Bsecond fifth of 371 graded peers; percentile 24.1, sampling error 2.5 points; lower is stronger |
| Rank | 90 of 371 |
| Profitability | Bpercentile 25.9 |
| Solvency | Cpercentile 53.7 |
| Growth and financing | B/Cpercentile 38.7 |
| Reliability | 0.94 AUCfailure model, filers with over $2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025 |
| Peer failure rate | 0.52% a yearItem 1.03 bankruptcies, same asset band, 2012 to 2025 |
| Size band | over $2.67B assetstotal assets $3.3B[1] |
| Standard universe | insiderevenue above $1M and assets above $10M[1-2] |
| Warnings | none active |
| Inputs computable | 9 of 14 |
| Graded from | filings received through Mar 2, 2026221 days before the rescan; every figure keyed to the SEC receipt date |
| Last close | $18.222026-10-08; market equity $1.9B; iex feed |
| Price used in grade | None |
| Share price, twelve months to the rescansplit-adjusted close; a lollipop at every rescan carries the letter held then; baseline ticks are SEC receipt dates of the inputs; ranges and dragging scroll the full history | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Percentile at every rescan on file, Jan 21, 2012 to Oct 9, 2026; stronger toward the top. Hover for the date. Open this report as it stood on | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Each date opens the report as it stood on that rescan. |
Business, in the company's words. Opening of Item 1 of the 10-K received Mar 2, 2026; the document on sec.gov.
We are a commercial-stage biopharmaceutical company focused on helping patients through the discovery and development of unique RNA-targeted therapeutics, siRNA knockdown therapies, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. Applying our proprietary, differentiated and innovative technologies, and through collaborations with our strategic partners, we have developed multiple approved products for the treatment of Duchenne muscular dystrophy ("Duchenne") and are developing potential therapeutic candidates for a broad range of diseases and disorders, including Duchenne and LGMD.
The Fourteen Inputs [top]
Lower percentile is stronger. Source numbers open the SEC filing; a range that spans filings opens the sources table.
| Input | Percentile, 0 to 100 | Value | Source | Peer median | Percentile | Peers | Period end |
|---|---|---|---|---|---|---|---|
| Profitability, sleeve percentile 25.9 | |||||||
| Gross profitability | 54.9% | [1-3] | 32.2% | 19.4 | 372 | 2025-12-31 | |
| Return on invested capital | not computable | 9.3% | |||||
| pretax income must exceed the validity floor and imply a 0%-100% tax rate | |||||||
| Accruals ratio | (13.9%) | [1,4-6] | (6.6%) | 32.3 | 811 | 2025-12-31 | |
| Gross margin stability, five years | not computable | 2.8 pts | |||||
| five annual gross margins are required; found 1 | |||||||
| Solvency, sleeve percentile 53.7 | |||||||
| Twelve-month failure probability | 0.04% | 0.07% | 30.4 | 248 | 2026-06-30 | ||
| Altman Z double-prime | (2.78) | [1,7-12] | (0.31) | 48.5 | 756 | 2025-12-31 | |
| Net debt to EBITDA | not computable | 1.82x | |||||
| EBITDA must exceed $100,000 | |||||||
| Interest coverage | (18.35x) | [10,13] | (4.51x) | 68.8 | 81 | 2025-12-31 | |
| Current ratio | 2.32x | [7-8] | 2.96x | 67.1 | 839 | 2025-12-31 | |
| Growth and financing, sleeve percentile 38.7 | |||||||
| Revenue growth, three-year compound | 30.2% | [2,14-16] | 10.0% | 21.5 | 415 | 2025-12-31 | |
| Free cash flow growth, three-year compound | not computable | 10.9% | |||||
| current FCF must be positive and base FCF must exceed $100,000 | |||||||
| Reinvestment rate | not computable | 37.1% | |||||
| pretax income must exceed the validity floor and imply a 0%-100% tax rate | |||||||
| Asset growth, three years | 2.3% | [1,6,17-18] | 2.1% | 46.1 | 704 | 2025-12-31 | |
| Net share issuance, one year | 8.2% | [19-20] | 2.5% | 48.7 | 634 | 2026-02-24 | |
Gross profitability. Revenue less cost of goods sold, over total assets.
Accruals ratio. Net income less operating cash flow, over average assets; lower is stronger.
Gross margin stability, five years. Standard deviation of gross margin; lower is stronger.
Twelve-month failure probability. CHS model; lower is stronger.
Net debt to EBITDA. Lower is stronger.
Net share issuance, one year. Split-adjusted; lower is stronger.
Sleeves are equal-weighted; within a sleeve each computable input carries equal weight. Composite -0.237; sampling error 2.5 percentile points on 371 peers.
Among 371 Peers [top]
Composite score of every graded peer, smoothed. Vertical rules are the letter band edges at the 20th, 40th, 60th and 80th percentiles. Small dots are the six largest peers by market equity.
| Rank | Company | Percentile | Letter | Warnings |
|---|---|---|---|---|
| 85 | Puma Biotechnology, Inc. (PBYI) Puma Biotechnology, Inc. (PBYI) Bsecond fifth; percentile 22.7 Nasdaq · Pharmaceutical Preparations market equity $514.7M; last close $9.99 Warnings: fortress balance sheet; 12 of 14 inputs | 22.7 | B | fortress balance sheet |
| 86 | Warby Parker Inc. (WRBY) Warby Parker Inc. (WRBY) Bsecond fifth; percentile 23.0 NYSE · Ophthalmic Goods market equity $2.8B; last close $24.96 No active warnings; 7 of 14 inputs | 23.0 | B | |
| 87 | Cronos Group Inc. (CRON) Cronos Group Inc. (CRON) Bsecond fifth; percentile 23.2 Nasdaq · Medicinal Chemicals & Botanical Products market equity $1.2B; last close $3.23 No active warnings; 9 of 14 inputs | 23.2 | B | |
| 88 | Guardant Health, Inc. (GH) Guardant Health, Inc. (GH) Bsecond fifth; percentile 23.5 Nasdaq · Services-Medical Laboratories market equity $22.2B; last close $165.62 No active warnings; 7 of 14 inputs | 23.5 | B | |
| 89 | Avalo Therapeutics, Inc. (AVTX) Avalo Therapeutics, Inc. (AVTX) Bsecond fifth; percentile 23.8 Nasdaq · Pharmaceutical Preparations market equity $720.3M; last close $13.43 Warnings: dilution, degenerate inputs; 7 of 14 inputs | 23.8 | B | dilution, degenerate inputs |
| 90 | Sarepta Therapeutics, Inc. (SRPT) Sarepta Therapeutics, Inc. (SRPT) Bsecond fifth; percentile 24.1 Nasdaq · Pharmaceutical Preparations market equity $1.9B; last close $18.22 No active warnings; 9 of 14 inputs | 24.1 | B | |
| 91 | Pulmonx Corp. (LUNG) Pulmonx Corp. (LUNG) Bsecond fifth; percentile 24.3 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $77.7M; last close $1.80 Warnings: fortress balance sheet; 8 of 14 inputs | 24.3 | B | fortress balance sheet |
| 92 | Amphastar Pharmaceuticals, Inc. (AMPH) Amphastar Pharmaceuticals, Inc. (AMPH) Bsecond fifth; percentile 24.6 Nasdaq · Pharmaceutical Preparations market equity $1.1B; last close $25.84 No active warnings; 13 of 14 inputs | 24.6 | B | |
| 93 | Mannatech Inc. (MTEX) Mannatech Inc. (MTEX) Bsecond fifth; percentile 24.9 Nasdaq · Medicinal Chemicals & Botanical Products market equity $15.2M; last close $7.79 Warnings: late filer, fortress balance sheet; 9 of 14 inputs | 24.9 | B | late filer, fortress balance sheet |
| 94 | NeuroPace Inc. (NPCE) NeuroPace Inc. (NPCE) Bsecond fifth; percentile 25.1 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $425.3M; last close $12.39 No active warnings; 9 of 14 inputs | 25.1 | B | |
| 95 | Zoetis Inc. (ZTS) Zoetis Inc. (ZTS) Bsecond fifth; percentile 25.4 NYSE · Pharmaceutical Preparations market equity $30.2B; last close $73.10 No active warnings; 9 of 14 inputs | 25.4 | B |
| Peer policy | Letter | Percentile | Peers |
|---|---|---|---|
| all graded filers, equal sleeves | B | 26.7 | 2204 |
| sector peers, equal sleeves (the grade) | B | 24.1 | 371 |
| same exchange, equal sleeves | B | 25.3 | 1219 |
| sector peers, equal inputs | B | 35.4 | 371 |
Each letter is one fifth of the 371 graded peers, about 74 companies. A boundary letter (A/B, B/C, C/D, D/E) marks a percentile within one sampling error of a band edge.
What the Price Implies [top]
Market measures at the 2026-10-08 close. None enters the grade. Percentile among graded peers with the same measure.
| Measure | Value | Peer median | Percentile | Reading |
|---|---|---|---|---|
| Twelve-month price change, skipping the latest month | 9.1% | 8.0% | 51 | hotter than 51 of 100 peers |
| Distance from 52-week high | (25.5%) | (31.4%) | 58 | closer to its high than 58 of 100 peers |
| EBIT to enterprise value | (31.8%) | (1.5%) | 19 | pricier than 81 of 100 peers |
| Free cash flow yield | (16.0%) | (1.0%) | 25 | pricier than 75 of 100 peers |
| Book value to price | 0.79 | 0.28 | 80 | pricier than 20 of 100 peers |
| Sales to price | 0.97 | 0.31 | 82 | pricier than 18 of 100 peers |
| Composite equity issuance, five years | 28.5% | 20.3% | 57 | more equity-funded than 57 of 100 peers |
| Relative strength against the sector, log excess return | (0.12) | (0.14) | 51 | ahead of 51 of 100 peers |
Inputs: market equity $1.9B; EBIT -$699.8M; free cash flow -$307.5M; book equity $1.5B; sales $1.9B; debt $847.6M; cash $571.1M[21].
Diagnostics [top]
Diagnostics do not feed the grade.
| Piotroski F-score: None of 9, period end 2025-12-31 | ||
|---|---|---|
| Return on assets above zero | (18.0%) | ✗ fail[4,6] |
| Operating cash flow above zero | -$205.5M | ✗ fail[5] |
| Return on assets improved | (25.2 pts) | ✗ fail[4,6,17,22] |
| Operating cash flow exceeds net income | $507.9M | ✓ pass[4-5] |
| Long-term leverage fell | (8.8 pts) | ✓ pass[1,6,17,23-24] |
| Current ratio improved | (188.3 pts) | ✗ fail[7-8,25-26] |
| No new shares issued | 8.2% | ✗ fail[19-20] |
| Gross margin improved | n/a[2-3] | |
| Asset turnover improved | (7.7 pts) | ✗ fail[2,6,14,17] |
| Cash, filings, liquidity | |
|---|---|
| Cash and equivalents | $571.1M[27] |
| Operating cash flow, four quarters | $111.0M[5,27-31] |
| Months of runway | not finite |
| trailing operating cash flow is nonnegative, so runway is not finite | |
| Late filings, two years | 0 |
| NT 10-K or NT 10-Q | |
| Days since last periodic filing | 65 |
| 10-Q received Aug 5, 2026 | |
| Median daily dollar volume | $49.4M |
| 63 sessions | |
| Days since newest grade input | 221 |
Downloads [top]
|
Sources [top]
Every citation on this page. Filing opens the SEC index page for that submission; viewer opens the SEC interactive data for the same filing; series opens the SEC XBRL API record for that tag and company.
| # | Concept | XBRL tag | Value | Period end | Received | Form | Links |
|---|---|---|---|---|---|---|---|
| 1 | assets | us-gaap:Assets | $3.3B | 2025-12-31 | 2026-03-02 | 10-K | filing · viewer · series |
| 2 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | $1.9B | 2025-12-31 | 2026-03-02 | 10-K | filing · viewer · series |
| 3 | cost of revenue | us-gaap:CostOfRevenue | $25.5M | 2025-12-31 | 2026-03-02 | 10-K | filing · viewer · series |
| 4 | net income | us-gaap:NetIncomeLoss | -$713.4M | 2025-12-31 | 2026-03-02 | 10-K | filing · viewer · series |
| 5 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$205.5M | 2025-12-31 | 2026-03-02 | 10-K | filing · viewer · series |
| 6 | assets | us-gaap:Assets | $4.0B | 2024-12-31 | 2026-03-02 | 10-K | filing · viewer · series |
| 7 | current assets | us-gaap:AssetsCurrent | $2.5B | 2025-12-31 | 2026-03-02 | 10-K | filing · viewer · series |
| 8 | current liabilities | us-gaap:LiabilitiesCurrent | $1.1B | 2025-12-31 | 2026-03-02 | 10-K | filing · viewer · series |
| 9 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$4.9B | 2025-12-31 | 2026-03-02 | 10-K | filing · viewer · series |
| 10 | operating income | us-gaap:OperatingIncomeLoss | -$699.8M | 2025-12-31 | 2026-03-02 | 10-K | filing · viewer · series |
| 11 | book equity | us-gaap:StockholdersEquity | $1.1B | 2025-12-31 | 2026-03-02 | 10-K | filing · viewer · series |
| 12 | liabilities | us-gaap:Liabilities | $2.2B | 2025-12-31 | 2026-03-02 | 10-K | filing · viewer · series |
| 13 | interest expense | us-gaap:InterestExpense | -$38.1M | 2025-12-31 | 2026-03-02 | 10-K | filing · viewer · series |
| 14 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | $1.8B | 2024-12-31 | 2026-03-02 | 10-K | filing · viewer · series |
| 15 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | $1.1B | 2023-12-31 | 2026-03-02 | 10-K | filing · viewer · series |
| 16 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | $843.8M | 2022-12-31 | 2025-02-28 | 10-K | filing · viewer · series |
| 17 | assets | us-gaap:Assets | $3.3B | 2023-12-31 | 2025-02-28 | 10-K | filing · viewer · series |
| 18 | assets | us-gaap:Assets | $3.1B | 2022-12-31 | 2024-02-28 | 10-K | filing · viewer · series |
| 19 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 104,989,772 | 2026-02-24 | 2026-03-02 | 10-K | filing · viewer · series |
| 20 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 97,032,073 | 2025-02-24 | 2025-02-28 | 10-K | filing · viewer · series |
| 21 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 105,627,021 | 2026-07-31 | 2026-08-05 | 10-Q | filing · viewer · series |
| 22 | net income | us-gaap:NetIncomeLoss | $235.2M | 2024-12-31 | 2026-03-02 | 10-K | filing · viewer · series |
| 23 | long term debt | us-gaap:LongTermDebt | $829.0M | 2025-12-31 | 2026-03-02 | 10-K | filing · viewer · series |
| 24 | long term debt | us-gaap:LongTermDebt | $1.1B | 2024-12-31 | 2026-03-02 | 10-K | filing · viewer · series |
| 25 | current assets | us-gaap:AssetsCurrent | $3.1B | 2024-12-31 | 2026-03-02 | 10-K | filing · viewer · series |
| 26 | current liabilities | us-gaap:LiabilitiesCurrent | $731.7M | 2024-12-31 | 2026-03-02 | 10-K | filing · viewer · series |
| 27 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $571.1M | 2026-06-30 | 2026-08-05 | 10-Q | filing · viewer · series |
| 28 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$5.6M | 2026-06-30 | 2026-08-05 | 10-Q | filing · viewer · series |
| 29 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$202.7M | 2026-03-31 | 2026-05-06 | 10-Q | filing · viewer · series |
| 30 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$336.7M | 2025-09-30 | 2025-11-06 | 10-Q | filing · viewer · series |
| 31 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$322.1M | 2025-06-30 | 2026-08-05 | 10-Q | filing · viewer · series |
Limitations [top]
Grade boundary. Percentile 24.1 is 4.1 points from the nearest band edge; sampling error is 2.5 points.
Peer group. Sector assignment from four-digit SIC codes, hand-tuned and published. The grade under three alternative peer policies is tabled above.
Size. Within a sector the letter tracks size. Among graded filers in the smallest asset band, 72% grade E and 0% grade A; in the largest, 13% grade E and 21% grade A. Universe as of Oct 9, 2026.
Failure model. filings 2012-01-01 to 2019-12-31 fit, filings 2020-01-01 to 2025-12-31 test; status post hoc pending confirmation. pre-registered on 2026 filings once their 12-month outcome windows close; supported if the paired per-quintile gain over the pooled model has a lower bound above 0.05.
Input validity. Revenue or total assets at or below $100,000 sets the degenerate-inputs flag. An input whose denominator is at or below $100,000 is left not computable rather than ranked.
Returns. No input on this page has a post-2015 confidence interval on returns that excludes zero. The grade ranks reported financial condition and is not a return forecast.
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
